[Discussion] can we stop arguing about dual agonist until somebody posts a number
Trying to get a straight answer on this: can we stop arguing about dual agonist until somebody posts a number.
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.
Are you comparing yourself with the trial mean or with the people who post the most?
This matches mine. Milder nausea than I expected, and what there was settled inside a fortnight of each step.
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
the four-week step schedule is the label, not folklore
the nausea profile is genuinely gentler than people expect coming from sema
Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.
Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
Push back: "gentler than sema" is a population statement.
sten_bhattacharya is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.
Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.
The step schedule question, answered properly, because it comes up weekly.
The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.
What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.
Same experience with the appetite effect being flatter across the week rather than front-loaded.
switching from sema is not a dose conversion, there is no clean equivalence
switching from sema is not a dose conversion, there is no clean equivalence
Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.
hold the dose that works, the ladder is not a leaderboard